Financial reports
Current reports
6-K
Current report (foreign)
17 Apr 24
6-K
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
2 Apr 24
6-K
Notice of Annual General Meeting
29 Mar 24
6-K
Evaxion Announces Business Update and Full Year 2023 Financial Results
27 Mar 24
6-K
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
19 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20 Feb 24
6-K
Current report (foreign)
7 Feb 24
6-K
Current report (foreign)
7 Feb 24
Registration and prospectus
424B4
Prospectus supplement with pricing info
5 Feb 24
F-1/A
Registration statement (foreign) (amended)
31 Jan 24
F-1/A
Registration statement (foreign) (amended)
31 Jan 24
F-1/A
Registration statement (foreign) (amended)
30 Jan 24
F-1
Registration statement (foreign)
12 Jan 24
424B4
Prospectus supplement with pricing info
13 Sep 23
POS AM
Prospectus update (post-effective amendment)
25 Aug 23
424B5
Prospectus supplement for primary offering
4 Oct 22
424B4
Prospectus supplement with pricing info
30 Aug 22
F-1/A
Registration statement (foreign) (amended)
22 Aug 22
Proxies
No filings
Other
EFFECT
Notice of effectiveness
2 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
UPLOAD
Letter from SEC
18 Jan 24
EFFECT
Notice of effectiveness
31 Aug 23
EFFECT
Notice of effectiveness
29 Aug 22
CORRESP
Correspondence with SEC
24 Aug 22
UPLOAD
Letter from SEC
12 Jul 22
EFFECT
Notice of effectiveness
6 Jun 22
CORRESP
Correspondence with SEC
1 Jun 22
UPLOAD
Letter from SEC
27 May 22
Ownership